Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 4/20 | 0.40 |
| ▸ | ITK | Q08881 | 4/20 | 0.40 |
| ▸ | BRAF | P15056 | 4/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23839117 | 0.81 | SYK (0.58) | SYKMAP3K5BRD4EGFRITK | |
| SCHEMBL1300326 | 0.79 | PRMT5 (0.47) | SYKBRD4PRMT5WDR77AAK1 | |
| SCHEMBL29895473 | 0.79 | PRMT5 (0.47) | SYKBRD4PRMT5WDR77AAK1 | |
| SCHEMBL20227776 | 0.78 | GSK3B (0.49) | PRMT5WDR77AAK1 | |
| SCHEMBL12567525 | 0.77 | AAK1 (0.48) | PRMT5WDR77AAK1 | |
| SCHEMBL29732643 | 0.77 | USP30 (0.44) | SYKPRMT5WDR77AAK1 | |
| SCHEMBL28446231 | 0.77 | USP30 (0.44) | SYKPRMT5WDR77AAK1 | |
| SCHEMBL20227780 | 0.77 | USP30 (0.44) | SYKPRMT5WDR77AAK1 | |
| SCHEMBL21083494 | 0.77 | USP30 (0.44) | SYKPRMT5WDR77AAK1 | |
| SCHEMBL21864818 | 0.77 | DGAT1 (0.41) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017484-A1 | INHIBITOR OF BRUTON TYROSINE KINASE | BEIJING RECIPROCAPHARMACEUTICALS CO., LTD. (CN) | 2022-01-20 | — | — | US | disclosed |
| EP-3882241-A1 | INHIBITOR OF BRUTON'S TYROSINE KINASE | Beijing Reciprocapharmaceuticals Co., Ltd. (CN) | 2021-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017484-A1 | INHIBITOR OF BRUTON TYROSINE KINASE | BTK, LYN, SYK | SYK 3/4885MAP3K5 144/4885BRD4 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.